These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 14557352

  • 1. Two better than one.
    SoRelle R.
    Circulation; 2003 Oct 14; 108(15):e9042-3. PubMed ID: 14557352
    [No Abstract] [Full Text] [Related]

  • 2. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH.
    Circulation; 2003 Oct 14; 108(15):1831-8. PubMed ID: 14517164
    [Abstract] [Full Text] [Related]

  • 3. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct 21; 146(43):58-9. PubMed ID: 15559524
    [No Abstract] [Full Text] [Related]

  • 4. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A, Suzuki Y, Saruta T.
    Hypertens Res; 1999 Mar 21; 22(1):17-22. PubMed ID: 10221346
    [Abstract] [Full Text] [Related]

  • 5. [Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
    Mundhenke M.
    Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2297-8; author reply 2298. PubMed ID: 17036279
    [No Abstract] [Full Text] [Related]

  • 6. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
    Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, Wozniak J, Zareba W, Szwed H.
    Am J Cardiol; 2010 Dec 01; 106(11):1609-14. PubMed ID: 21094362
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aldosterone antagonism in heart failure.
    Richards AM, Nicholls MG.
    Lancet; 1999 Sep 04; 354(9181):789-90. PubMed ID: 10485716
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
    MMW Fortschr Med; 2004 Oct 21; 146(43):59. PubMed ID: 15559525
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aldosterone blockade after myocardial infarction.
    Hackam DG.
    CMAJ; 2003 Sep 02; 169(5):444. PubMed ID: 12952808
    [No Abstract] [Full Text] [Related]

  • 20. [Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
    Trifonov IR.
    Kardiologiia; 2003 Sep 02; 43(6):71-2. PubMed ID: 12974260
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.